Esperion Therapeutics ESPR Unrealized Losses on Investments (Before Tax)
Unrealized Losses on Investments (Before Tax) at other companies
Other financials
Where this comes from
Reported directly by Esperion Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax.
The official record: Esperion Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Esperion Therapeutics's unrealized losses on investments (before tax).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Esperion Therapeutics's unrealized losses on investments (before tax)?
- Esperion Therapeutics (ESPR) reported unrealized losses on investments (before tax) of $0 in Q1 2026.
- What does unrealized losses on investments (before tax) mean?
- This represents the cumulative decrease in the fair market value of investment securities held by the company that have not yet been sold, measured before tax effects. It highlights the potential volatility and risk exposure within the company's investment portfolio. Investors monitor this to gauge the impact of market fluctuations on the company's balance sheet.